Morgan Stanley Upgrades Centessa Pharmaceuticals (CNTA) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
B.Riley Starts Centessa Pharmaceuticals (CNTA) at Buy
September 18, 2024 4:43 PM EDTB.Riley initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating and a price target of $33.00.
For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.
Shares of Centessa Pharmaceuticals closed at $16.28 yesterday.
... More